Structural Heart Leader Offers $140 Million Compensation Package to New CFO

Edwards Lifesciences Corp. (NYSE: EW) has announced that it has entered into an employment and sign-on bonus agreement with its incoming Chief Financial Officer, Theodora Doretta Mistras. Under the two-year arrangement, Mistras will receive a base salary of approximately $925,000 and more than $10 million in new compensation—including cash and equity—equivalent to roughly KRW 14 billion.

The company reported first-quarter 2026 revenue of $1.65 billion, up 16.7% year over year. Driven by strong performance in its structural heart therapy portfolio, Edwards Lifesciences raised its full-year revenue growth guidance to 9–11% and modestly increased its adjusted earnings-per-share outlook. It also completed a $500 million accelerated share repurchase program and ended the quarter with about $2.4 billion in cash and cash equivalents against approximately $600 million in total debt.

In a May 4 filing and press release, Edwards Lifesciences confirmed that Mistras will officially succeed current CFO Scott Ullem as corporate vice president and CFO on May 29, finalizing its executive succession plan.

Following the first-quarter results, several brokerages maintained a “buy” rating on Edwards Lifesciences, citing growth in structural heart products and the upgraded guidance, and highlighted the company’s compelling medium- to long-term growth story.

Edwards Lifesciences is a U.S.-based company specializing in medical devices for structural heart disease, including transcatheter heart valves and cardiovascular monitoring equipment. Its core offerings include the SAPIEN transcatheter aortic valve replacement system and the PASCAL and EVOQUE platforms for treating mitral and tricuspid valve disease.

With global expansion in the transcatheter heart valve and structural heart therapy markets fueled by aging populations and the growing adoption of minimally invasive cardiac procedures, the company aims to sustain its leadership through ongoing R&D and robust clinical data generation.